New analytic tools: backward compatibility enhances scanning laser tomography

Article

Stability of technology is important when dealing with patients who have a progressive disease, said Balwantray Chauhan, PhD, professor and director of research, Department of Ophthalmology, Dalhousie University, Halifax, Nova Scotia.

Stability of technology is important when dealing with patients who have a progressive disease, said Balwantray Chauhan, PhD, professor and director of research, Department of Ophthalmology, Dalhousie University, Halifax, Nova Scotia.

When technology is continually upgraded, clinicians sometimes find that they are no longer able to view images taken years ago, which is clearly a disadvantage in dealing with slowly progressing conditions such as glaucoma, Dr. Chauhan said. Confocal scanning laser tomography (which was developed 25 years ago) lends itself to backward compatibility, however.

As a glaucoma specialist, Dr. Chauhan is interested in variability over a short period; when this is known, one can set limits that define change and establish criteria for change. Several techniques have been developed to help clinicians measure change with confocal scanning laser tomography.

Both statistic image mapping (SIM) and topographic change analysis (TCA) are effective techniques for detecting topographic change in series of images, Dr. Chauhan said.

"With both SIM and TCA, you can apply images that were captured in the early 1990s, for example, and start to reveal things that weren't really obvious at the time because of the backward compatibility," Dr. Chauhan said.

In evaluating images, it is also important to be able to correct for spatial correlation, Dr. Chauhan concluded. Doing so considerably decreases the amount of noise that may affect the accuracy of the interpretation.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
© 2024 MJH Life Sciences

All rights reserved.